Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.

Adverse events will be closely watched when full data are reported.

The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.

Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.

The Avanzar study could read out shortly.